Current Report Filing (8-k)
09 Junio 2023 - 4:31PM
Edgar (US Regulatory)
0001722964
false
0001722964
2023-06-08
2023-06-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): June 8, 2023
Y-MABS THERAPEUTICS, INC.
(Exact name of registrant as specified
in its charter)
Delaware |
|
001-38650 |
|
47-4619612 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
230 Park Avenue
Suite 3350
New York, New York 10169
(Address of principal executive offices)
(Zip Code)
(646) 885-8505
(Registrant’s telephone number,
include area code)
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class: |
|
Trading Symbol |
|
Name of each exchange on which
registered: |
Common Stock, $0.0001 par value |
|
YMAB |
|
Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.07 |
Submission of Matters to a Vote of Security Holders |
On June 8, 2023, Y-mAbs Therapeutics, Inc. (the “Company”)
held its annual meeting of stockholders (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the
stockholders of the Company voted on the following three proposals: (1) the election of three Class II directors, James I. Healy, M.D.,
Ashutosh Tyagi, M.D. and Laura J. Hamill, each to hold office until the Company’s 2026 Annual Meeting of Stockholders, subject to
the election and qualification of his or her successor or to his or her earlier death, resignation or removal, (“Proposal 1”);
(2) the ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company
for its fiscal year ending December 31, 2023 (“Proposal 2”); and (3) the approval, in a non-binding advisory vote, of the
compensation of the Company’s named executive officers as disclosed in the proxy materials (“Proposal 3”). The final
results of the voting on each proposal are set forth below.
Proposal 1 - Election of Directors
The Company’s stockholders elected the three persons listed below
as directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders, subject to the election and qualification of
his or her successor or to his or her earlier death, resignation or removal. The votes cast were as follows:
Nominees |
|
For |
|
Withheld |
|
Broker Non-Votes |
James I. Healy, M.D. |
|
17,547,627 |
|
|
4,394,531 |
|
|
4,478,802 |
|
Ashutosh Tyagi, M.D. |
|
16,091,327 |
|
|
5,850,831 |
|
|
4,478,802 |
|
Laura J. Hamill |
|
16,797,068 |
|
|
5,145,090 |
|
|
4,478,802 |
|
Proposal 2 – Ratification of the Appointment of the Independent
Registered Public Accounting Firm
The Company’s stockholders approved Proposal 2. The votes cast
were as follows:
For |
|
Against |
|
Abstain |
26,405,976 |
|
|
2,239 |
|
|
12,745 |
|
Proposal 3 – Advisory Vote on the Compensation of the Named
Executive Officers
The Company’s stockholders approved Proposal 3. The votes cast
were as follows:
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
15,934,564 |
|
|
5,999,462 |
|
|
8,132 |
|
|
4,478,802 |
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Y-MABS THERAPEUTICS, INC. |
|
|
|
Date: June 9, 2023 |
By: |
/s/ Thomas Gad |
|
|
Thomas Gad |
|
|
Founder, President, Interim Chief Executive Officer and Head of Business Development & Strategy |
Y mAbs Therapeutics (NASDAQ:YMAB)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024